An Open-label, Dose-escalation, Bi-weekly Phase I+II Clinical Trial in Treating Patients With Limited Stage of High-grade Osteosarcoma of Maintenance Therapy After Adjuvant Chemotherapy
Latest Information Update: 29 Jun 2023
At a glance
- Drugs Socazolimab (Primary)
- Indications Osteosarcoma
- Focus Adverse reactions
- Sponsors Zhaoke Pharmaceutical (Hefei)
- 05 Dec 2022 Results (n=21; Between October 2018 and October 2019) assessing the safety and preliminary efficacy of ZKAB001 as maintenance therapy for localized high-grade osteosarcoma patients to reduce the risk of recurrence and metastasis, published in the Clinical Cancer Research.
- 17 Sep 2018 Status changed to recruiting.
- 22 Mar 2018 According to Lee's Pharmaceutical Holdings Limited website, the Company has received approval to proceed with the clinical trials for ZKAB001. Clinical data from this trial is expected to be available by the end of 2019, and positive results could lead to conditional approval of the antibody prior to a confirmatory Phase III study. Link: http://www.leespharm.com/file/investor/LTN20180322470.pdf